AstraZeneca(US:AZN) Di Yi Cai Jing·2025-04-29 21:50Group 1 - The company AstraZeneca is facing potential fines related to unpaid taxes on imported cancer drugs, specifically $8 million for the drug Enhertu and up to $4.5 million for Imfinzi and Imjudo [1][1] - In the first quarter of this year, AstraZeneca reported total revenue of $13.6 billion, which was below analyst expectations of $13.8 billion, primarily due to lower-than-expected sales of oncology drugs [3] - The CEO of AstraZeneca, Pascal Soriot, stated that the impact of potential tariffs on imported drugs from Europe would be manageable, and the company aims to maintain its performance guidance for 2025 [3][3] Group 2 - AstraZeneca announced a $2.5 billion investment plan to establish its sixth global strategic R&D center in Beijing, reflecting the company's commitment to the Chinese market and confidence in its life sciences ecosystem [4] - The company has not disclosed any updates regarding the investigation of its former China president, who was taken away for alleged smuggling [4]